CClinicalTrials.gg
CompletedNCT04752111Updated Oct 1, 2021

Dose Esmolol Infusion Have an Adjuvant Effect to TAP Block for Pain Control in Laparoscopic Cholecystectomy.

A Phase 4 interventional study of Esmolol in Postoperative Pain, sponsored by Benha University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2021-10-01.

Sponsored by Benha University · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Pain after laparoscopy differs considerably from that seen after laparotomy. Laparotomy results mainly in parietal pain (abdominal wall), where as Pain in laparoscopy results from stretching of the intra-abdominal cavity, peritoneal inflammation, and diaphragmatic irritation caused by residual carbon-dioxide in the peritoneal cavity. The transverse abdominis plane (TAP) block is a peripheral nerve block designed to anesthetize the nerves supplying the anterior abdominal wall (T6 to L1). While esmolol is an ultra-short acting intravenous β-blocker having a rapid onset and offset effect. It provides an unprecedented level of tolerability and safety in the perioperative setting. When used as an adjunct, it has been shown to improve the postoperative recovery by reducing postoperative pain intensity and intraoperative anesthetic and opioid requirements and preventing opioid-induced hyperalgesia . The mechanism of this synergistic effect is uncertain, but both pharmacokinetic and pharmacodynamics interactions with anesthetic drugs have been proposed.

02

Conditions studied

  • Postoperative Pain

Browse trials for

Keywords

  • Esmolol infusion
  • TAP block
  • cholecystectomy
03

In context

Pain, Postoperative

5,093 studies on the registry are indexed under Pain, Postoperative; 1,140 are open to participants now.

This study's enrollment of 60 is below the median of 75 across 4,344 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

Benha University is the lead sponsor of 356 studies on the registry; 68 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. ASA grade I/II patients undergoing laparoscopic cholecystectomy .
  2. Age group of 18 -60 years.
  3. Patients giving valid informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Patient refusal
  2. Patients belonging to ASA grade III and grade IV .
  3. Coagulation disorders.
  4. Patients with known allergy to one of the used drugs.
  5. Extreme obesity (BMI >35)
  6. Patients with cardiac, pulmonary, hepatic or renal disorders
  7. Pregnancy
  8. Drug abusers
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Group E (esmolol infusion)

    10 minutes before induction of anesthesia the patients will receive a loading dose of injection esmolol 0.5 mg/kg in 30 ml isotonic saline in the IV line, followed by an IV infusion of esmolol 0.05 mg/kg/min till the completion of surgery After induction of anesthesia and before starting the surgery, patients will receive bilateral in-plane ultrasound guided transversus abdominis plane block with 40 ml of bupivacaine 0. 25% after induction of anesthesia 20 ml in each side .

    Drug: Esmolol

  • Placebo comparator
    Group T (TAP block)

    10 minutes before induction of anesthesia the patients will receive a loading dose of injection 30 ml isotonic saline in the iv line, followed by an IV infusion of saline at a rate of 0.05 mg/kg/min till the completion of surgery After induction of anesthesia and before starting the surgery, patients will receive bilateral in-plane ultrasound guided transversus abdominis plane block with 40 ml of bupivacaine 0. 25% after induction of anesthesia 20 ml in each side.

    Drug: Esmolol

Interventions

  • DrugEsmolol

    administration of a loading dose esmolol infusion 0.5 mg/kg in 30 ml isotonic saline in the IV line, followed by an IV infusion of esmolol 0.05 mg/kg/min till the completion of surgery

06

What researchers measure

Primary outcomes

  1. pain rescue-analgesia consumption

    . If pain score exceed 3, rescue analgesia 5 mg bolus of morphine will be administered intravenous to achieve satisfactory pain control that can be repeated every 4-6 hours.

    Time frame: 24 hours postoperative

Secondary outcomes

  1. Visual analogue pain score

    scales from zero (no pain) to ten (unbearable pain)

    Time frame: every 0,2,4,6,12, up to 24 hours postoperative

  2. Intraoperative hemodynamic data

    mean arterial blood pressure and heart rate

    Time frame: 30 minutes after induction of anesthesia

  3. Postoperative nausea and vomiting

    A three-point rating scale (1: no postoperative nausea and vomiting, 2: nausea without vomiting, 3: nausea with vomiting. Ondansetron 4 mg will be available if required.

    Time frame: 24 hours postoperative

  4. Patient satisfaction

    using a 5-point Likert scale (1 was "very unsatisfied", 2- "unsatisfied", 3- "unsure", 4- "satisfied", and 5- "very satisfied").

    Time frame: 24 hours postoperative

07

Study locations

1 site
  • Samar Rafik Mohamed Amin
    Benha, Qalubia 13511, Egypt
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04752111
Lead sponsor
Benha University
Responsible party
Samar Rafik Mohamed Amin (lecturer of anesthesia and surgical ICU, Benha University) — Principal investigator
First posted
Feb 12, 2021
Start date
Jan 19, 2021
Primary completion
Jun 15, 2021
Completion
Jul 20, 2021
Last update
Oct 1, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion